Low dose mesenchymal stem cells
Phase 2Cell therapy
Low dose mesenchymal stem cells is one of 73 biologic programs targeting Systemic Lupus Erythematosus. It is currently in Phase 2.
2
Indications
3
Total Trials
1
Active Trials
72
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
778 competitors in Osteoarthritis
#DrugCompanyPhaseTrials
1Epidiolex
Jazz PharmaceuticalsPreclinical
Toradol
RochePreclinical
Platelet Rich Plasma
ZZagazig University
Preclinical
Voltaren
CCerimon Pharmaceuticals
Preclinical
Cataflam
NovartisPreclinical
Bayer Aspirin
BayerPreclinical
Enbrel
IImmunex
Preclinical
Low dose mesenchymal stem cells
SSclnow Biotechnology Co., Ltd.
Phase 2
Glucophage
Boehringer IngelheimPreclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Systemic Lupus Erythematosus2 trials
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 2[1]
- Company
- SSclnow Biotechnology Co., Ltd.